Table 3 Comparison between patients with synchronous and metachronous metastases regarding lesions size and SUV on 18F-FDG PET/CT study
From: 18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer
Site | Item | Synchronous No. = 35 | Metachronous No. = 44 | P1 | P2 | ||||
|---|---|---|---|---|---|---|---|---|---|
Baseline Mean ± Std | F.U Mean ± Std | P | Baseline Mean ± Std | F.U Mean ± Std | P | ||||
Prim. Site | Size | 5.8 ± 2.8 | 3.0 ± 1.09 | 0.00** | 0.000 | 0.000 | 0.00** | 0.00** | 0.00** |
SUV | 16.7 ± 6.8 | 7.6 ± 2.9 | 0.00** | 0.000 | 0.000 | 0.00** | 0.00** | 0.00** | |
LNs mets | Size | 1.5 ± 0.6 | 1.3 ± 0.4 | 0.08 | 1.8 ± 0.7 | 1.1 ± 1.0 | 0.001** | 0.026* | 0.027* |
SUV | 4.5 ± 2.5 | 3.1 ± 1.3 | 0.00** | 4.7 ± 1.3 | 2.9 ± 3.0 | 0.00** | 0.01* | 0.034* | |
Liver mets | Size | 2.4 ± 1.6 | 2.3 ± 0.9 | 0.62 | 2.3 ± 0.8 | 2.1 ± 0.9 | 0.21 | 0.41 | 0.93 |
SUV | 10.3 ± 4.4 | 6.6 ± 1.7 | 0.93 | 8.8 ± 2.6 | 7.2 ± 3.5 | 0.16 | 0.008* | 0.07 | |
Periton.mets | Size | 2.7 ± 1.0 | 2.4 ± 0.7 | 0.71 | 3.03 ± 1.2 | 2.2 ± 1.2 | 0.41 | 0.31 | 0.39 |
SUV | 10.1 ± 11.3 | 6.8 ± 2.0 | 0.25 | 8.7 ± 4.7 | 6.8 ± 2.4 | 0.00** | 0.74 | 0.98 | |
Lung mets | Size | 1.4 ± 0.4 | 1.3 ± 0.4 | 0.23 | 1.0 ± 0.3 | 1.0 ± 0.5 | 0.52 | 0.11 | 0.11 |
SUV | 6.7 ± 2.4 | 4.4 ± 2.3 | 0.002* | 3.9 ± 0.7 | 3.7 ± 0.7 | 0.51 | 0.22 | 0.002* | |
Bone mets | SUV | 8.7 ± 2.6 | 6.8 ± 4.9 | 0.52 | 6.8 ± 4.9 | 3.9 ± 0.8 | 0.50 | 0.12 | 0.098 |